vs
Healthpeak Properties（DOC）与Lantheus Holdings, Inc.（LNTH）财务数据对比。点击上方公司名可切换其他公司
Healthpeak Properties的季度营收约是Lantheus Holdings, Inc.的1.8倍（$719.4M vs $406.8M），Healthpeak Properties净利率更高（73.2% vs 13.3%，领先59.9%），Lantheus Holdings, Inc.同比增速更快（4.0% vs 3.1%），Healthpeak Properties自由现金流更多（$357.0M vs $81.4M），过去两年Healthpeak Properties的营收复合增速更高（8.9% vs 4.9%）
Healthpeak Properties是美国医疗地产领域的房地产投资信托基金，核心投资范畴覆盖老年住宅、生命科学相关物业及医疗办公楼三类资产。公司2007年于马里兰州组建，总部设在科罗拉多州丹佛市，在尔湾、纳什维尔、旧金山均设有办事处，截至2019年12月31日共持有617处物业的权益。
Lantheus Holdings是一家全球性医疗保健企业，专注于研发、生产及商业化创新诊断显像剂与相关解决方案，产品覆盖肿瘤学、心脏病学、泌尿学等核心医疗领域，主要市场遍及北美及全球其他重点地区。
DOC vs LNTH — 直观对比
营收规模更大
DOC
是对方的1.8倍
$406.8M
营收增速更快
LNTH
高出0.9%
3.1%
净利率更高
DOC
高出59.9%
13.3%
自由现金流更多
DOC
多$275.6M
$81.4M
两年增速更快
DOC
近两年复合增速
4.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $719.4M | $406.8M |
| 净利润 | $114.0M | $54.1M |
| 毛利率 | — | 59.2% |
| 营业利润率 | 17.4% | 19.0% |
| 净利率 | 73.2% | 13.3% |
| 营收同比 | 3.1% | 4.0% |
| 净利润同比 | 2406.4% | 558.8% |
| 每股收益（稀释后） | $0.16 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOCLNTH
| Q4 25 | $719.4M | $406.8M | ||
| Q3 25 | $705.9M | $384.0M | ||
| Q2 25 | $694.3M | $378.0M | ||
| Q1 25 | $702.9M | $372.8M | ||
| Q4 24 | $698.0M | $391.1M | ||
| Q3 24 | $700.4M | $378.7M | ||
| Q2 24 | $695.5M | $394.1M | ||
| Q1 24 | $606.6M | $370.0M |
净利润DOCLNTH
| Q4 25 | $114.0M | $54.1M | ||
| Q3 25 | $-117.1M | $27.8M | ||
| Q2 25 | $31.7M | $78.8M | ||
| Q1 25 | $42.8M | $72.9M | ||
| Q4 24 | $4.5M | $-11.8M | ||
| Q3 24 | $85.9M | $131.1M | ||
| Q2 24 | $146.0M | $62.1M | ||
| Q1 24 | $6.7M | $131.1M |
毛利率DOCLNTH
| Q4 25 | — | 59.2% | ||
| Q3 25 | 58.6% | 57.9% | ||
| Q2 25 | 60.2% | 63.8% | ||
| Q1 25 | 61.1% | 63.8% | ||
| Q4 24 | 60.3% | 63.5% | ||
| Q3 24 | 60.0% | 63.9% | ||
| Q2 24 | 60.6% | 64.9% | ||
| Q1 24 | 59.8% | 65.4% |
营业利润率DOCLNTH
| Q4 25 | 17.4% | 19.0% | ||
| Q3 25 | 9.2% | 11.4% | ||
| Q2 25 | 5.7% | 23.3% | ||
| Q1 25 | 7.7% | 27.4% | ||
| Q4 24 | -2.2% | 29.1% | ||
| Q3 24 | 14.1% | 35.3% | ||
| Q2 24 | 22.3% | 26.1% | ||
| Q1 24 | 3.7% | 28.8% |
净利率DOCLNTH
| Q4 25 | 73.2% | 13.3% | ||
| Q3 25 | -16.6% | 7.2% | ||
| Q2 25 | 4.6% | 20.8% | ||
| Q1 25 | 6.1% | 19.6% | ||
| Q4 24 | 0.7% | -3.0% | ||
| Q3 24 | 12.3% | 34.6% | ||
| Q2 24 | 21.0% | 15.8% | ||
| Q1 24 | 1.1% | 35.4% |
每股收益（稀释后）DOCLNTH
| Q4 25 | $0.16 | $0.86 | ||
| Q3 25 | $-0.17 | $0.41 | ||
| Q2 25 | $0.05 | $1.12 | ||
| Q1 25 | $0.06 | $1.02 | ||
| Q4 24 | $0.02 | $-0.18 | ||
| Q3 24 | $0.12 | $1.79 | ||
| Q2 24 | $0.21 | $0.88 | ||
| Q1 24 | $0.01 | $1.87 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $467.5M | $359.1M |
| 总债务越低越好 | $9.8B | $568.7M |
| 股东权益账面价值 | $7.5B | $1.1B |
| 总资产 | $20.3B | $2.2B |
| 负债/权益比越低杠杆越低 | 1.31× | 0.52× |
8季度趋势，按日历期对齐
现金及短期投资DOCLNTH
| Q4 25 | $467.5M | $359.1M | ||
| Q3 25 | $91.0M | $382.0M | ||
| Q2 25 | $89.4M | $695.6M | ||
| Q1 25 | $70.6M | $938.5M | ||
| Q4 24 | $119.8M | $912.8M | ||
| Q3 24 | $180.4M | $866.4M | ||
| Q2 24 | $106.9M | $757.0M | ||
| Q1 24 | $101.8M | $718.3M |
总债务DOCLNTH
| Q4 25 | $9.8B | $568.7M | ||
| Q3 25 | $9.1B | $567.9M | ||
| Q2 25 | $9.0B | $566.8M | ||
| Q1 25 | $8.9B | $566.1M | ||
| Q4 24 | $8.7B | $565.3M | ||
| Q3 24 | $8.6B | $613.0K | ||
| Q2 24 | $8.6B | $563.2M | ||
| Q1 24 | $8.8B | $562.5M |
股东权益DOCLNTH
| Q4 25 | $7.5B | $1.1B | ||
| Q3 25 | $7.6B | $1.1B | ||
| Q2 25 | $7.9B | $1.2B | ||
| Q1 25 | $8.2B | $1.2B | ||
| Q4 24 | $8.4B | $1.1B | ||
| Q3 24 | $8.6B | $1.2B | ||
| Q2 24 | $8.8B | $1.0B | ||
| Q1 24 | $8.9B | $945.5M |
总资产DOCLNTH
| Q4 25 | $20.3B | $2.2B | ||
| Q3 25 | $19.6B | $2.3B | ||
| Q2 25 | $19.8B | $2.1B | ||
| Q1 25 | $19.8B | $2.1B | ||
| Q4 24 | $19.9B | $2.0B | ||
| Q3 24 | $20.0B | $2.0B | ||
| Q2 24 | $20.2B | $1.9B | ||
| Q1 24 | $20.5B | $1.8B |
负债/权益比DOCLNTH
| Q4 25 | 1.31× | 0.52× | ||
| Q3 25 | 1.20× | 0.51× | ||
| Q2 25 | 1.14× | 0.49× | ||
| Q1 25 | 1.08× | 0.49× | ||
| Q4 24 | 1.04× | 0.52× | ||
| Q3 24 | 1.00× | 0.00× | ||
| Q2 24 | 0.98× | 0.55× | ||
| Q1 24 | 0.99× | 0.59× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3B | $90.2M |
| 自由现金流经营现金流 - 资本支出 | $357.0M | $81.4M |
| 自由现金流率自由现金流/营收 | 49.6% | 20.0% |
| 资本支出强度资本支出/营收 | 124.4% | 2.2% |
| 现金转化率经营现金流/净利润 | 10.99× | 1.67× |
| 过去12个月自由现金流最近4个季度 | — | $354.1M |
8季度趋势，按日历期对齐
经营现金流DOCLNTH
| Q4 25 | $1.3B | $90.2M | ||
| Q3 25 | $315.0M | $105.3M | ||
| Q2 25 | $363.5M | $87.1M | ||
| Q1 25 | $279.4M | $107.6M | ||
| Q4 24 | $1.1B | $157.7M | ||
| Q3 24 | $318.2M | $175.1M | ||
| Q2 24 | $316.2M | $84.7M | ||
| Q1 24 | $152.6M | $127.2M |
自由现金流DOCLNTH
| Q4 25 | $357.0M | $81.4M | ||
| Q3 25 | — | $94.7M | ||
| Q2 25 | — | $79.1M | ||
| Q1 25 | — | $98.8M | ||
| Q4 24 | $333.7M | $141.4M | ||
| Q3 24 | — | $159.3M | ||
| Q2 24 | — | $73.5M | ||
| Q1 24 | — | $119.0M |
自由现金流率DOCLNTH
| Q4 25 | 49.6% | 20.0% | ||
| Q3 25 | — | 24.7% | ||
| Q2 25 | — | 20.9% | ||
| Q1 25 | — | 26.5% | ||
| Q4 24 | 47.8% | 36.1% | ||
| Q3 24 | — | 42.0% | ||
| Q2 24 | — | 18.7% | ||
| Q1 24 | — | 32.2% |
资本支出强度DOCLNTH
| Q4 25 | 124.4% | 2.2% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.1% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | 105.6% | 4.2% | ||
| Q3 24 | — | 4.2% | ||
| Q2 24 | — | 2.8% | ||
| Q1 24 | — | 2.2% |
现金转化率DOCLNTH
| Q4 25 | 10.99× | 1.67× | ||
| Q3 25 | — | 3.79× | ||
| Q2 25 | 11.48× | 1.11× | ||
| Q1 25 | 6.52× | 1.47× | ||
| Q4 24 | 235.43× | — | ||
| Q3 24 | 3.71× | 1.34× | ||
| Q2 24 | 2.17× | 1.36× | ||
| Q1 24 | 22.85× | 0.97× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOC
暂无分部数据
LNTH
| Radiopharmaceutical Oncology | $240.2M | 59% |
| Definity | $85.3M | 21% |
| Strategic Partnerships And Other | $23.3M | 6% |
| Techne Lite | $21.0M | 5% |
| Licenseand Royalty Revenues | $17.4M | 4% |
| Other | $13.6M | 3% |
| Other Precision Diagnostics | $5.9M | 1% |
